Table 1.
Baseline and other characteristics by completion status of the EOT survey
| Completed EOT survey (N=65) | Did not complete EOT survey (N=54) | P-value1 | |
|---|---|---|---|
| Treatment arm as randomized – n (%) | 0.46 | ||
| Cabozantinib | 31 (47.7%) | 30 (55.6%) | |
| Mitoxantrone | 34 (52.3%) | 24 (44.4%) | |
| Age in years – median (range) | 65 (53–79) | 66.5 (44–80) | 0.17 |
| Race – n (%) | 0.75 | ||
| White | 55 (84.6%) | 45 (83.3%) | |
| Black | 5 (7.7%) | 6 (11.1%) | |
| Other | 5 (7.7%) | 3 (5.6%) | |
| Country – n (%) | 0.01 | ||
| Australia | 11 (16.9%) | 7 (13.0%) | |
| Canada | 8 (12.3%) | 2 (3.7%) | |
| United Kingdom | 5 (7.7%) | 16 (29.6%) | |
| United States | 41 (63.1%) | 29 (53.7%) | |
| ECOG Performance Status – n (%) | 0.16 | ||
| 0–1 | 60 (92.3%) | 45 (83.3%) | |
| ≥2 | 5 (7.7%) | 9 (16.7%) | |
| Prior Cabazitaxel – n (%) | 21 (32.3%) | 28 (51.9%) | 0.04 |
| End of treatment reason – n (%) | 0.02 | ||
| Disease progression | 42 (64.6%) | 22 (40.7%) | |
| Adverse event | 12 (18.5%) | 13 (24.1%) | |
| Other/unknown | 11 (16.9%) | 19 (35.2%) |
EOT, end of treatment; ECOG, Eastern Cooperative Oncology Group
1
P-values are based on Wilcoxon rank-sum test for age and Fisher’s exact test for all other characteristics.